A common cholesterol drug called atorvastatin can reduce the growth of leaky new blood vessels inside artery plaques, even when it doesn’t lower cholesterol much—this might help prevent plaques from bursting.
Evidence Quality Assessment
Claim Status
overstated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study uses mouse models and in vitro cells; it cannot establish causation in humans. The claim implies a direct biological effect, but the evidence only supports an association in a specific animal model.
More Accurate Statement
“Atorvastatin is associated with a 30% reduction in intraplaque angiogenesis and a 34% reduction in immature neovessels in hypercholesterolemic ApoE3*Leiden mice with vein graft atherosclerosis, independent of cholesterol-lowering effects.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Evidence from Studies
Supporting (1)
Atorvastatin pleiotropically decreases intraplaque angiogenesis and intraplaque haemorrhage by inhibiting ANGPT2 release and VE-Cadherin internalization
The study gave mice a cholesterol-lowering drug called atorvastatin and found it made dangerous new blood vessels inside plaque shrink — even when cholesterol levels were the same as in mice not given the drug. This means the drug works directly on the vessels, not just by lowering cholesterol.